- PR Newswire•12 hours ago
LA JOLLA, Calif., Dec. 6, 2016 /PRNewswire/ -- Regulus Therapeutics Inc. (RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced two new drug development candidates at its R&D day, held in New York. "We are delighted to announce the addition of two new drug candidates to our growing portfolio of potential microRNA therapeutics.
- PR Newswire•15 days ago
LA JOLLA, Calif., Nov. 22, 2016 /PRNewswire/ -- Regulus Therapeutics Inc. (RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it will host a R&D day on Tuesday, December 6, 2016 from 8:30 a.m. to 11:30 a.m. EST in New York City where it plans to announce new development candidates. Interested parties may access a live audio webcast and slides of the presentations on the investor section of Regulus' website at www.regulusrx.com beginning at 8:30 a.m. EST.
- Capital Cube•last month
Categories: ETFs Yahoo Finance Click here to see latest analysis ETF’s with exposure to Regulus Therapeutics, Inc. Here are 5 ETF’s with the largest exposure to RGLS-US. Comparing the performance and risk of Regulus Therapeutics, Inc. with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
RGLS : Summary for Regulus Therapeutics Inc. - Yahoo Finance
Regulus Therapeutics Inc. (RGLS)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
|Day's Range||2.50 - 3.00|
|52 Week Range||2.13 - 10.18|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-2.02|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|